- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01601262
Efficacy & Safety of a 2nd Series of Low Intensity Shock Waves for ED on Partial Responders to First Treatment
Efficacy and Safety of a Second Series of Low Intensity Extracorporeal Shock Wave Therapy (LI-ESWT) Treatment for Erectile Dysfunction Patients Who Were Partial Responders to the Initial Treatment.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The patients will be selected out of the patients with Erectile Dysfunction who received Low intensity shock waves and Were Partial Responders to the treatment.
At the first meeting the patient will receive a full explanation of the study, the potential efficacy and risks. After that the patient will be asked to sign an informed consent form. The patient's general medical condition and any problems related to sexual dysfunction are already known from the previous study he was participating. Also the patient's sexual function is already known by sexual function questionnaires that were filled out in previous study. The criteria for inclusion and exclusion will be reviewed, as well as physical examination. Then shall the patient obtain reporting sexual encounter diaries (SEP) and will be asked to avoid using PDE5i's for a month (washout), if he did not do so of some reason after ending the previous study, then it would be the first visit (Visit 1). At visit 1 The patient will be questioning the sexual function questionnaires without PDE5i's and will pass examination performance Endothelial - FMD, the test takes about 10 minutes, it is not an invasive test (not involved in inserting an instrument or any medication) and is painless. The patient may be asked to also undergo Doppler ultrasound. At the end of visit 1 the patient will begin Series of 12 treatments, in which the subject will be treated twice a week for 3 weeks (6 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for 3 weeks (6 treatments). Four weeks after the treatment series ends the patient will come for another visit and will be asked to fill in questionnaires and perform the FMD and/or Doppler ultrasound test again. The patient's ED condition will be followed up for a long term after the end of his participation in the study.
Studietype
Registrering (Forventet)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
-
Haifa, Israel
- Rambam Health Care Campus
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Incomplete response to active treatment (not placebo) on first round but patient is still unsatisfied.
- Recurring ED (had improved on first round of shock wave therapy but after a certain period of time became clinically worse again) after shock wave therapy.
- A minimum of two sexual attempts per month.
- An IIEF-ED domain score ≤ 25 post screening, with or without PDE5i intake according to assessment on final visit of Shockwave previous treatment.
- A stable heterosexual relationship with the same partner for more than three months
Exclusion Criteria:
- Subjects that did not respond at all to the first round as well as those that did not respond sufficiently.
- Any pelvic surgery during the period after the first round.
- Any unstable medical or psychiatric condition, spinal cord injury, or penile anatomical abnormalities arising during this period .
- cardiovascular conditions that prevent sexual activity.
- Recent Use of anti-androgens, or oral or injectable androgens
- Recent hormonal, neurologic, or psychological pathology
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Åpen etikett
|
We will apply the cardiospec 1000 unit for LI-ESWL in the penile and inguinal areas, 300 shocks per area, total of 1500 shocks.
Full description of treatment series can be seen in the detailed protocol.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
IIEF-ED Domain score
Tidsramme: 3 months
|
Severe ED (6≤IIEF-ED Domain score≤10): an increase of 7 points and above; Moderate ED (11≤IIEF-ED Domain score≤16): an increase of 5 points and above; Mild ED (17≤IIEF-ED Domain score≤25): an increase of 2 points and above.
|
3 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Rigidity Score Questionaire
Tidsramme: 3 months
|
An increase of at least 1 point is considered as a treatment success.
|
3 months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Ilan Gruenwald, MD, Rambam Health Care Campus
- Studieleder: Yoram Vardi, Prof. MD, Rambam Health Care Campus
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 0179-12-RMB
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Erektil dysfunksjon
-
Consorcio Centro de Investigación Biomédica en...Hospital General Universitario Gregorio Marañon; Universidad Complutense... og andre samarbeidspartnereHar ikke rekruttert ennåLeverfibrose/NASH | MASH - Metabolic Dysfunction-Associated Steatohepatitt | MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseSpania
-
Assiut UniversityUkjentPacemaker Lead DysfunctionItalia
-
Bursa Postgraduate HospitalFullførtPacemaker Lead Dysfunction | Manuell trekkraft
-
Rivus Pharmaceuticals, Inc.RekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatittForente stater
-
University of ChicagoFullførtICD | Enhetsfeil | Pacemaker Lead DysfunctionForente stater
-
Madrigal Pharmaceuticals, Inc.RekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatittForente stater
-
Shanghai East HospitalRekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatittKina
-
Southern California Institute for Research and...Har ikke rekruttert ennåMASH - Metabolic Dysfunction-Associated Steatohepatitt
-
Nabiqasim Industries (Pvt) LtdRekrutteringMASH - Metabolic Dysfunction-Associated SteatohepatittPakistan
-
Fondazione Policlinico Universitario Agostino Gemelli...RekrutteringMASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseItalia